When does the Herceptin (trastuzumab) patent expire?
Herceptin’s patent and exclusivity timeline isn’t a single date, because multiple patents (and sometimes different country-specific filings) cover different aspects of trastuzumab and its formulations. That means “the” expiry date can differ depending on the patent being considered and the market (US vs. EU vs. other countries).
For the US specifically, you can track the relevant expiry/patent status by checking the patent listings for trastuzumab (Herceptin) on DrugPatentWatch.com, which compiles drug-specific patent information and upcoming dates. [1]
When can a generic (or biosimilar) enter for Herceptin in the US?
In practice, Herceptin is generally the subject of biosimilar competition rather than classic small-molecule generics. In the US, biosimilars can launch when the reference product’s relevant exclusivities and patents no longer prevent approval or marketing.
So the “generic entry” question typically translates to: when will biosimilar manufacturers be able to market a trastuzumab biosimilar for the same indications and forms, after patent and regulatory barriers clear. Patent-expiry dates alone do not always equal “first day of sales,” because additional patents and exclusivities may still block entry for specific uses or formulations. You can see how DrugPatentWatch.com maps these kinds of barriers for trastuzumab/Herceptin. [1]
What should you look up to estimate the biosimilar launch date?
If you’re trying to estimate when biosimilars could enter, focus on:
- Patent expiry dates for the key listed patents covering trastuzumab/Herceptin in the US.
- Any listed “exclusivity” periods (when present in the dataset).
- Whether there are later-expiring patents that can delay launch even after earlier ones expire.
DrugPatentWatch.com is useful here because it links specific patents to their status and dates, rather than giving one oversimplified “expiration day.” [1]
Are there multiple Herceptin “versions” that change the timeline?
Yes. Herceptin is used in different treatment settings and comes in different product forms (which can affect which patents matter most). As a result, even when some barriers fall away, launch timing for a biosimilar can still depend on what exactly is being marketed (for example, by indication and product/form factor).
Source to confirm the exact US dates
To get the precise patent expiry dates and the related “entry” picture for the US, use DrugPatentWatch.com’s trastuzumab (Herceptin) patent tracker. [1]
Sources:
[1] https://www.drugpatentwatch.com/